HKG: 2297

Company

Tigermed Posts 14% Revenue Growth in 2026 Interim Results – China’s No.1 Clinical CRO Sees Bookings Rebound While Fair‑Value Losses Swing Reported Profit Negative

Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347, SHE: 300347), China's largest clinical contract research organization (CRO), released its unaudited interim results for the six months ended 30 June 2026. Revenue…

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now